Skip to content

Gabapentin in the Post-cesarean Pain Management of Buprenorphine Patient

A Randomized, Double-blind, Placebo-controlled Trial of Gabapentin in the Post-cesarean Pain Management of Buprenorphine Patient

Status
Withdrawn
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03335436
Enrollment
0
Registered
2017-11-07
Start date
2018-04-01
Completion date
2020-12-31
Last updated
2019-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean Delivery, Pain Management

Keywords

buprenorphine maintenance

Brief summary

The purpose of this study is to determine whether a perioperative course of gabapentin in parturients on buprenorphine maintenance would improve analgesia after elective cesarean delivery (CD).

Detailed description

Many strategies have been suggested to improve post-CD pain management in parturients on buprenorphine. While effective pain relief can be achieved, women maintained on buprenorphine during pregnancy have been shown to require up to 50% more opioids after CD compared to women with opioid use disorder not on a maintenance regimen. The perioperative use of gabapentin has been shown to reduce pain scores and opioid consumption following a variety of surgeries, ranging from cardiac bypass to total abdominal hysterectomy. The purpose of this study is to determine whether a perioperative course of gabapentin in parturients on buprenorphine maintenance would improve analgesia after elective CD.

Interventions

DRUGGabapentin

Participants will receive Gabapentin 600 mg by mouth one hour prior to scheduled cesarean delivery and 400 mg by mouth every 8 hours post delivery

DRUGPlacebo

Participants will receive Placebo with similar appearance to gabapentin by mouth one hour prior to scheduled cesarean delivery and by mouth every 8 hours post delivery

Sponsors

Vanderbilt University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* singleton, term pregnancy * currently on buprenorphine maintenance therapy * scheduled for elective CD under spinal anesthesia

Exclusion criteria

* use illicit drugs or relapse during the last trimester of pregnancy * positive drug screen at the time of delivery * allergies to any medications used in the study * taking prescribed gabapentin at the time of admission for CD * contraindications to neuraxial anesthesia or require general anesthesia for CD * designated ASA physical status 4 or above

Design outcomes

Primary

MeasureTime frameDescription
Total opioid use 24 hours after cesarean delivery24 hours after cesarean deliveryTotal opioid use tallied in morphine milligram equivalents at 24 hours after cesarean delivery
Total opioid use at time of hospital discharge after cesarean deliveryFrom the end of cesarean delivery to the time of hospital discharge after cesarean delivery, approximately 4 daysTotal opioid use tallied in morphine milligram equivalents from the end cesarean delivery to the time of hospital discharge after cesarean delivery

Secondary

MeasureTime frameDescription
Pain assessment using 11-point Visual/Verbal Analog (VAS) at rest 24 hours post-partum24 hours post-partumPain assessment using VAS at rest 24 hours post-partum when 0 is no pain and 10 is worst pain
Pain assessment using 11-point Visual/Verbal Analog (VAS) at movement 24 hours post-partum24 hours post-partumPain assessment using VAS at movement 24 hours post-partum when 0 is no pain and 10 is worst pain
Pain assessment using 11-point Visual/Verbal Analog (VAS) at rest 48 hours post-partum48 hours post-partumPain assessment using VAS at rest 48 hours post-partum when 0 is no pain and 10 is worst pain
Pain assessment using 11-point Visual/Verbal Analog (VAS) at movement 48 hours post-partum48 hours post-partumPain assessment using VAS at movement 48 hours post-partum when 0 is no pain and 10 is worst pain
Pain assessment using 11-point Visual/Verbal Analog (VAS) at rest 4 hours post-partum4 hours post-partumPain assessment using VAS at rest 4 hours post-partum when 0 is no pain and 10 is worst pain
Pain assessment using 11-point Visual/Verbal Analog (VAS) at movement 30 days post-partum30 days post-partumPain assessment using VAS at movement 30 days post-partum when 0 is no pain and 10 is worst pain
Presence of persistent pain30 days post-partumPresence of persistent pain defined as pain score greater than baseline at 30 days post-partum
Return to normal daily function30 days post-partumReturn to normal daily function assessed with the Veterans RAND 12-item questionnaire
Pain assessment using 11-point Visual/Verbal Analog (VAS) at rest 30 days post-partum30 days post-partumPain assessment using VAS at rest 30 days post-partum when 0 is no pain and 10 is worst pain
Pain assessment using 11-point Visual/Verbal Analog (VAS) at movement 4 hours post-partum4 hours post-partumPain assessment using VAS at movement 4 hours post-partum when 0 is no pain and 10 is worst pain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026